Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12419665 | 0.82 | MEN1 (0.60) | MEN1KMT2ADRD2ACHEHDAC1 | |
| SCHEMBL19697827 | 0.80 | MEN1 (0.54) | MEN1KMT2AALDH1A1DRD2ACHE | |
| SCHEMBL3397349 | 0.77 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1LMNADRD2 | |
| SCHEMBL14924016 | 0.76 | HRH3 (0.57) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL18580991 | 0.76 | HRH3 (0.67) | MEN1KMT2AALDH1A1ACHEHRH3 | |
| SCHEMBL24240460 | 0.76 | MEN1 (0.55) | MEN1KMT2AALDH1A1LMNADRD2 | |
| SCHEMBL22804562 | 0.76 | SLC18A3 (0.49) | DRD2 | |
| SCHEMBL22804564 | 0.76 | SLC18A3 (0.49) | DRD2 | |
| Bromide SCHEMBL22804321 | 0.75 | DRD2 (0.47) | DRD2HRH3 | |
| SCHEMBL17465246 | 0.74 | HRH3 (0.69) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | MEN1 4220/4885KMT2A 2097/4885ALDH1A1 354/4885 |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | MEN1 4220/4885KMT2A 2097/4885ALDH1A1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.